Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms
December 03 2018 - 8:30AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced expanded global access of the company’s quality controls
across multiple Abbott clinical diagnostics platforms that now
includes the Abbott Alinity ci-series instruments.
“We are pleased to fulfill this need and offer customers access
to Bio-Rad’s quality control products and solutions for many Abbott
clinical diagnostics platforms,” said John Hertia, Bio-Rad
President, Clinical Diagnostics Group. “Bio-Rad’s comprehensive
suite of quality controls and data management solutions combined
with our customer training and support services help to strengthen
the performance of clinical labs, ensuring that the most reliable
data is provided to physicians and, most importantly, to the
patient.”
Bio-Rad is a global leader of quality control products, offering
an extensive range of quality controls covering analytes for
immunoassay, chemistry, cardiac assessment, immunology, diabetes,
coagulation, hematology, blood gas, drugs-of-abuse, and infectious
disease testing. The company’s QC data management solutions connect
large peer groups of test systems and assay methods to the
company’s Unity Interlaboratory Program, enabling labs to compare
their results in real time with over 25,000 other labs
worldwide.
For further information, please
visit http://www.qcnet.com/partners.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.1 billion in 2017. For more information,
please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our expectations
regarding our products. Forward-looking statements generally can be
identified by the use of forward-looking terminology such as
“will”, “believe,” “expect,” “anticipate,” “may,” “plan,” “intend,”
“estimate,” “offers,” or similar expressions or the negative of
those terms or expressions, although not all forward-looking
statements contain these words. Such statements involve risks and
uncertainties, which could cause actual results to vary materially
from those expressed in or indicated by the forward-looking
statements. These risks and uncertainties include our ability to
develop and market new or improved products, our ability to compete
effectively, international legal and regulatory risks, and product
quality and liability issues. For further information regarding our
risks and uncertainties, please refer to the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operation” in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
Bio-Rad cautions you not to place undue reliance on forward-looking
statements, which reflect an analysis only and speak only as of the
date hereof. We disclaim any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181203005164/en/
Bio-Rad Laboratories, Inc.Tina Cuccia, Corporate
Communications510-724-7000tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024